Incidence of psychiatric side effects during pegylated interferon- α retreatment in nonresponder hepatitis C virus-infected patients
Article first published online: 16 AUG 2007
Volume 27, Issue 8, pages 1098–1102, October 2007
How to Cite
Quarantini, L. C., Bressan, R. A., Galvão, A., Batista-Neves, S., Paraná, R. and Miranda-Scippa, Â. (2007), Incidence of psychiatric side effects during pegylated interferon- α retreatment in nonresponder hepatitis C virus-infected patients. Liver International, 27: 1098–1102. doi: 10.1111/j.1478-3231.2007.01532.x
- Issue published online: 16 AUG 2007
- Article first published online: 16 AUG 2007
- Received 12 December 2006accepted 8 April 2007
- hepatitis C;
- psychiatric side effects;
Objective: Evaluate the incidence of mental disorders using pegylated interferon plus ribavirin retreatment in nonresponder hepatitis C virus-infected patients.
Method: The Mini-International Neuropsychiatric Interview (MINI) was used to evaluate 30 hepatitis C virus-infected interferon-nonresponder patients at baseline and following 4, 12 and 24 weeks of pegylated interferon retreatment.
Results: During the pegylated interferon/ribavirin retreatment, 5(16.6%) patients developed psychiatric side effects: 3(10%) were diagnosed with major depressive disorder, 1(3.3%) had a brief psychotic disorder and 1(3.3%) presented with panic attacks.
Conclusion: This is the first prospective study evaluating the incidence of neuropsychiatric side effects during interferon retreatment of hepatitis C virus-infected patients, suggesting that the risk of acquiring serious psychiatric symptoms during retreatment with interferon-α (IFN-α) may not be higher than during the first antiviral therapy. This finding challenges the hypothesis that during a second treatment with IFN-α, patients with hepatitis C may be at greater risk for neuropsychiatric side effects than naïve patients.